Nycomed Says Phase III Daxas COPD Data Show Drug Is Ready For A Second Shot

The privately held European pharma is looking for a U.S. partner to commercialize the potentially first-in-class PDE4 inhibitor.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet